Iih - latest news (December 2, 2022)

Invex Therapeutics (ASX:IXC) receives green light for IIH trial in NZ


Invex Therapeutics (ASX:IXC) has been given the green light by the New Zealand Medicinesand Medical Devices Safety Authority ...
The Market Herald | 7 days ago
Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin


Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has randomised the first idiopathic intracranial ...
smallcaps | 3 days ago
Invex Therapeutics recruits first idiopathic intracranial hypertension patient to Presendin trial


The ASX will open higher on Monday, tracking New York’s gains on Friday US housing data shows a possible recession ... Read ...
Stockhead on MSN | 10 days ago
Peptron Inc.: Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin


It is almost scary to assess that a woman may have symptoms of cancer, something is bothering her; but she chooses to stay ...
Women's Web | 3 days ago
Market Highlights: US recession fears, tighter crypto rules, and 5 ASX small caps to watch on Monday


Cannabis stock, Zelira Therapeutics (ASX:ZLD), announced that it has completed the enrolment for its Diabetic Nerve Pain Drug ...
stockhead on MSN | 11 days ago
jG |
© 2022 Latest news Taiwan